Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide.
Anagrelide, a phospholipase A2 inhibitor, is widely used in the management of essential thrombocythemia. To date, anagrelide has only rarely been reported to be associated with the development of drug-induced interstitial pneumonitis. We herein report two cases of anagrelide-associated interstitial pneumonitis. The patients were a 67-year-old woman and a 75-year-old man, both with essential thrombocythemia. Both cases developed interstitial pneumonitis at 8 weeks after administration of anagrelide. Because anagrelide-induced interstitial pneumonitis was suspected from CT scan and bronchoalveolar lavage fluid findings, anagrelide-therapy was discontinued and corticosteroid administration was initiated. Anagrelide withdrawal and corticosteroid administration resulted in marked symptom amelioration. A lymphocyte stimulation test using anagrelide was positive in both cases. As interstitial pneumonitis is a rare adverse event during anagrelide-therapy administration, physicians must be vigilant in identifying drug-induced interstitial pneumonitis in patients treated with anagrelide because early detection can decrease the severity and prevent mortality.
Department of Hematology and Oncology, Tosei General Hospital.
Tomohiro
T
Kajiguchi
Sonoko
S
Kamoshita
Takayasu
T
Ito
Mitsuaki
M
Yagi
Tomoki
T
Kimura
D000368:Aged; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011014:Pneumonia / Q000175:diagnosis / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide